| SKU | Size | Availability | Price | Qty |
|---|---|---|---|---|
| rp143784-10μg | 10μg | In stock | $99.90 | |
| rp143784-20μg | 20μg | In stock | $138.90 | |
| rp143784-100μg | 100μg | In stock | $366.90 | |
| rp143784-1mg | 1mg | Available within 8-12 weeks(?) Production requires sourcing of materials. We appreciate your patience and understanding. | $2,334.90 |
Animal Free, >95%(SDS-PAGE), Active, 293F, His&Fc tag, 23-618aa
| Product Name | Recombinant Human gp130 Protein, ＞95%(SDS-PAGE), high purity |
|---|---|
| Synonyms | CD130 antigen | CD130 | CDw130 | DKFZp564F053 | gp130 of the rheumatoid arthritis antigenic peptide-bearing soluble form | gp130 | IL-6 receptor subunit beta | IL-6R subunit beta | IL-6RB | IL-6R-beta | IL6ST | interleukin 6 signal transducer (gp130, onco |
| Grade | ActiBioPure™, Animal Free, Azide Free, Bioactive, Carrier Free, High Performance |
| Product Description | Function Signal-transducing molecule. The receptor systems for IL6, LIF, OSM, CNTF, IL11, CTF1 and BSF3 can utilize gp130 for initiating signal transmission. Binds to IL6/IL6R (alpha chain) complex, resulting in the formation of high-affinity IL6 binding sites, and transduces the signal. Does not bind IL6. May have a role in embryonic development (By similarity). The type I OSM receptor is capable of transducing OSM-specific signaling events. Post-translational Phosphorylation of Ser-782 down-regulates cell surface expression. Heavily N-glycosylated. |
| Specifications & Purity | ActiBioPure™, Bioactive, Animal Free, Carrier Free, Azide Free, High performance, ≥95%(SDS-PAGE) |
| Purity | ＞95%(SDS-PAGE) |
| Bioactivity | Measured by its ability to inhibit IL-6-dependent proliferation of the 7TD1 mouse hybridoma cells in the presence of Recombinant Human IL-6 R alpha.The ED₅₀ for this effect is 0.65-6.5 ng/mL. |
| Endotoxin Concentration | <0.01 EU/μg |
| Expression System | HEK293 |
| Species | Human |
| Amino Acids | 23-618 aa |
| Sequence | ELLDPCGYISPESPVVQLHSNFTAVCVLKEKCMDYFHVNANYIVWKTNHFTIPKEQYTIINRTASSVTFTDIASLNIQLTCNILTFGQLEQNVYGITIISGLPPEKPKNLSCIVNEGKKMRCEWDGGRETHLETNFTLKSEWATHKFADCKAKRDTPTSCTVDYSTVYFVNIEVWVEAENALGKVTSDHINFDPVYKVKPNPPHNLSVINSEELSSILKLTWTNPSIKSVIILKYNIQYRTKDASTWSQIPPEDTASTRSSFTVQDLKPFTEYVFRIRCMKEDGKGYWSDWSEEASGITYEDRPSKAPSFWYKIDPSHTQGYRTVQLVWKTLPPFEANGKILDYEVTLTRWKSHLQNYTVNATKLTVNLTNDRYLATLTVRNLVGKSDAAVLTIPACDFQATHPVMDLKAFPKDNMLWVEWTTPRESVKKYILEWCVLSDKAPCITDWQQEDGTVHRTYLRGNLAESKCYLITVTPVYADGPGSPESIKAYLKQAPPSKGPTVRTKKVGKNEAVLEWDQLPVDVQNGFIRNYTIFYRTIIGNETAVNVDSSHTEYTLSSLTSDTLYMVRMAAYTDEGGKDGPEFTFTTPKFAQGEI |
| Protein Tag | C-Fc & His |
| N-terminal Sequence | Glu |
| Accession # | P40189 |
| Predicted molecular weight | 95 kDa |
Recombinant Human gp130 Protein (rp143784) - Protein Bioactivity
Measured by its ability to inhibit IL-6-dependent proliferation of the 7TD1 mouse hybridoma cells in the presence of Recombinant Human IL-6 R alpha. The ED₅₀ for this effect is 2.4 ng/mL.
Recombinant Human gp130 Protein (rp143784) - SDS-PAGE
4 μg/lane of Recombinant Human gp130 was resolved with SDS-PAGE under reducing (R) and non-reducing (N) conditions and visualized by Coomassie® Blue staining, showing a band at 122.7 kDa under reducing conditions and 250.0 kDa under non-reducing conditions.
| Form | Lyophilized |
|---|---|
| Reconstitution | Reconstitute in water to a concentration of 0.1-1.0 mg/ml. |
| Storage Temp | Store at -20°C,Avoid repeated freezing and thawing |
| Shipped In | Ice chest + Ice pads |
| Stability And Storage | 12 months from date of receipt, -20 to -70 ℃ as supplied. 1 month, 2 to 8 ℃ under sterile conditions after reconstitution. 3 months, -20 to -70 ℃ under sterile conditions after reconstitution. |
Enter Lot Number to search for COA:
Find and download the COA for your product by matching the lot number on the packaging.
| Lot Number | Certificate Type | Date | Item |
|---|---|---|---|
 ZJ23F1201894 | Certificate of Analysis | Dec 13, 2023 | rp143784 |
| ZJ23F1201895 | Certificate of Analysis | Dec 13, 2023 | rp143784 |
| ZJ23F1201896 | Certificate of Analysis | Dec 13, 2023 | rp143784 |
| 1. Boulanger MJ, Chow DC, Brevnova EE, Garcia KC. (2003) Hexameric structure and assembly of the interleukin-6/IL-6 alpha-receptor/gp130 complex.. Science, 300 (5628): (2101-4). [PMID:12829785] [10.1021/op500134e] |
| 2. Bravo J, Staunton D, Heath JK, Jones EY. (1998) Crystal structure of a cytokine-binding region of gp130.. EMBO J, 17 (6): (1665-74). [PMID:9501088] [10.1021/op500134e] |
| 3. Wilde MI, Faulds D. (1998) Oprelvekin: a review of its pharmacology and therapeutic potential in chemotherapy-induced thrombocytopenia.. BioDrugs, 10 (2): (159-71). [PMID:18020592] [10.1021/op500134e] |
| 4. Berl T, Schwertschlag U. (2000) Preclinical pharmacologic basis for clinical use of rhIL-11 as an effective platelet-support agent.. Oncology (Williston Park, NY), 14 (9 Suppl 8): (12-20). [PMID:11033834] [10.1021/op500134e] |
| 5. Van Roy M, Ververken C, Beirnaert E, Hoefman S, Kolkman J, Vierboom M, Breedveld E, 't Hart B, Poelmans S, Bontinck L et al.. (2015) The preclinical pharmacology of the high affinity anti-IL-6R Nanobody® ALX-0061 supports its clinical development in rheumatoid arthritis.. Arthritis Res Ther, 17 (13): (135). [PMID:25994180] [10.1021/op500134e] |
| 6. Anna Wonnerth,Katharina M Katsaros,Konstantin A Krychtiuk,Walter S Speidl,Christoph Kaun,Kylie Thaler,Kurt Huber,Johann Wojta,Gerald Maurer,Ingebjorg Seljeflot,Harald Arnesen,Thomas W Weiss. (2014-03-19) Glycoprotein 130 polymorphism predicts soluble glycoprotein 130 levels.. Metabolism: clinical and experimental, 63 ((5)): (647-653). [PMID:24629561] |
| 7. Li H, Xiao H, Lin L, Jou D, Kumari V, Lin J, Li C.. (2014) Drug design targeting protein-protein interactions (PPIs) using multiple ligand simultaneous docking (MLSD) and drug repositioning: discovery of raloxifene and bazedoxifene as novel inhibitors of IL-6/GP130 interface.. J Med Chem, 57 (3): (632-641). [PMID:24456369] [10.1021/jm401144z] |
| 8. Song D,Yu W,Ren Y,Zhu J,Wan C,Cai G,Guo J,Zhang W,Kong L. (2020) Discovery of bazedoxifene analogues targeting glycoprotein 130.. Eur J Med Chem, 199 (112375-112375). [PMID:32388278] [10.1016/j.ejmech.2020.112375] |
| 9. Hibi, M M and 5 more authors.. (1990) Molecular cloning and expression of an IL-6 signal transducer, gp130.. Cell, (21): [PMID:2261637] |
| 10. Mosley, B B and 6 more authors.. (1996) Dual oncostatin M (OSM) receptors. Cloning and characterization of an alternative signaling subunit conferring OSM-specific receptor activation.. The Journal of biological chemistry, (20): [PMID:8999038] |
| 11. Gibson, R M RM and 5 more authors.. (2000) Phosphorylation of human gp130 at Ser-782 adjacent to the Di-leucine internalization motif. Effects on expression and signaling.. The Journal of biological chemistry, (21): [PMID:10811661] |
| 12. Tanaka, M M and 7 more authors.. (2000) Cloning of novel soluble gp130 and detection of its neutralizing autoantibodies in rheumatoid arthritis.. The Journal of clinical investigation, [PMID:10880057] |
| 13. Moritz, R L RL, Hall, N E NE, Connolly, L M LM and Simpson, R J RJ.. (2001) Determination of the disulfide structure and N-glycosylation sites of the extracellular domain of the human signal transducer gp130.. The Journal of biological chemistry, (16): [PMID:11098061] |
| 14. Jostock, T T and 8 more authors.. (2001) Soluble gp130 is the natural inhibitor of soluble interleukin-6 receptor transsignaling responses.. European journal of biochemistry, [PMID:11121117] |
| 15. Li, H H, Wang, H H and Nicholas, J J.. (2001) Detection of direct binding of human herpesvirus 8-encoded interleukin-6 (vIL-6) to both gp130 and IL-6 receptor (IL-6R) and identification of amino acid residues of vIL-6 important for IL-6R-dependent and -independent signaling.. Journal of virology, [PMID:11238858] |
| 16. Chow , D D, He , X X, Snow, A L AL, Rose-John, S S and Garcia, K C KC.. (2001) Structure of an extracellular gp130 cytokine receptor signaling complex.. Science (New York, N.Y.), (16): [PMID:11251120] |
| 17. Boulanger, Martin J MJ, Bankovich, Alexander J AJ, Kortemme, Tanja T, Baker, David D and Garcia, K Christopher KC.. (2003) Convergent mechanisms for recognition of divergent cytokines by the shared signaling receptor gp130.. Molecular cell, [PMID:14527405] |
| 18. Schmutz, Jeremy J and 75 more authors.. (2004) The DNA sequence and comparative analysis of human chromosome 5.. Nature, (16): [PMID:15372022] |
| 19. Liu, Tao T and 6 more authors.. () Human plasma N-glycoproteome analysis by immunoaffinity subtraction, hydrazide chemistry, and mass spectrometry.. Journal of proteome research, [PMID:16335952] |
| 20. Sjöblom, Tobias T and 28 more authors.. (2006) The consensus coding sequences of human breast and colorectal cancers.. Science (New York, N.Y.), (13): [PMID:16959974] |
| 21. Zahedi, René P RP and 8 more authors.. (2008) Phosphoproteome of resting human platelets.. Journal of proteome research, [PMID:18088087] |
| 22. Hashimoto, Yuichi Y, Kurita, Megumi M, Aiso, Sadakazu S, Nishimoto, Ikuo I and Matsuoka, Masaaki M.. (2009) Humanin inhibits neuronal cell death by interacting with a cytokine receptor complex or complexes involving CNTF receptor alpha/WSX-1/gp130.. Molecular biology of the cell, [PMID:19386761] |
| 23. Waetzig, Georg H GH and 12 more authors.. (2010) N-linked glycosylation is essential for the stability but not the signaling function of the interleukin-6 signal transducer glycoprotein 130.. The Journal of biological chemistry, (15): [PMID:19915009] |
| 24. Xu, Yibin Y and 9 more authors.. (2010) Crystal structure of the entire ectodomain of gp130: insights into the molecular assembly of the tall cytokine receptor complexes.. The Journal of biological chemistry, (9): [PMID:20489211] |
| 25. Schütt, Antje A and 6 more authors.. (2013) gp130 activation is regulated by D2-D3 interdomain connectivity.. The Biochemical journal, (15): [PMID:23294003] |
| 26. Sun, Luguo L and 8 more authors.. () Low incidence of IL6ST (gp130) mutations in exon 6 in lung cancer of a Chinese cohort.. Cancer genetics, [PMID:25242236] |
| 27. Taniguchi, Koji K and 17 more authors.. (2015) A gp130-Src-YAP module links inflammation to epithelial regeneration.. Nature, (5): [PMID:25731159] |
| 28. Lokau, Juliane J and 13 more authors.. (2016) Proteolytic Cleavage Governs Interleukin-11 Trans-signaling.. Cell reports, (23): [PMID:26876177] |
| 29. Schwerd, Tobias T and 24 more authors.. (2017) A biallelic mutation in IL6ST encoding the GP130 co-receptor causes immunodeficiency and craniosynostosis.. The Journal of experimental medicine, (4): [PMID:28747427] |
| 30. Shahin, Tala T and 16 more authors.. (2019) Selective loss of function variants in IL6ST cause Hyper-IgE syndrome with distinct impairments of T-cell phenotype and function.. Haematologica, [PMID:30309848] |
| 31. Chen, Yin-Huai and 26 more authors.. (2020) Absence of GP130 cytokine receptor signaling causes extended Stüve-Wiedemann syndrome.. The Journal of experimental medicine, (2): [PMID:31914175] |
| 32. Béziat, Vivien and 59 more authors.. (2020) Dominant-negative mutations in human IL6ST underlie hyper-IgE syndrome.. The Journal of experimental medicine, (1): [PMID:32207811] |
| 33. Materna-Kiryluk, Anna and 17 more authors.. (2021) Mosaic IL6ST variant inducing constitutive GP130 cytokine receptor signaling as a cause of neonatal onset immunodeficiency with autoinflammation and dysmorphy.. Human molecular genetics, (30): [PMID:33517393] |
